Full Press Release Details
FIBROGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018
Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced
Unresectable Pancreatic Cancerr
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, August 7, 2018 -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today reported financial results for the second quarter of 2018 and provided an update on the company's recent developments.
"We are encouraged by the progress of our discussions with the FDA in advancing the development of pamrevlumab in IPF and locally advanced pancreatic cancer into pivotal Phase 3 clinical trials, including with the potential for accelerated approval in LAPC," said Thomas B. Neff, FibroGen's Chief Executive Officer. "Meanwhile, we are on track with timelines for regulatory submission of roxadustat for the treatment of CKD anemia in multiple regions, as we have made significant progress toward approval in China, and our studies for US approval are completing and will read out in the fourth quarter of this year."
Recent Developments and Highlights
Roxadustat for Anemia in Chronic Kidney Disease (CKD) in the U.S./EU
Roxadustat for Anemia in CKD in China
Roxadustat for Anemia Associated with MDS in China
Roxadustat for Anemia in CKD in Japan
Pamrevlumab for Idiopathic Pulmonary Fibrosis (IPF)
Pamrevlumab for Pancreatic Cancer
Corporate and Financial
Conference Call and Webcast Details
FibroGen will host a conference call and webcast today, Tuesday, August, 7, 2018, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update. A live audio webcast of the call may be accessed in the investor section of the company's website, www.fibrogen.com. To participate in the conference call by telephone, please dial 1 (888) 771-4371 (U.S. and Canada) or 1 (847) 585-4405 (international), reference the FibroGen second quarter 2018 financial results conference call, and use passcode 47339190#. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial 1 (888) 843-7419 (domestic) or 1 (630) 652-3042 (international), and use passcode 47339190#.
Roxadustat (FG-4592) is a first-in-class, orally administered small molecule currently in global Phase 3 clinical development as a potential therapy for anemia associated with chronic kidney disease (CKD). Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis - increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients, including in the presence of inflammation and without a need for supplemental intravenous iron.
Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in patients with CKD in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in patients with CKD in the U.S., China, and other markets.
Roxadustat is advancing through Phase 3 clinical trials worldwide, with multiple trials completed. The Phase 3 program is supported by extensive Phase 2 clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. Globally, the Phase 3 program encompasses a total of 15 Phase 3 studies to support independent regulatory approvals of roxadustat in both non-dialysis-dependent and dialysis-dependent CKD patients in the U.S., Europe, Japan, and China. Roxadustat is currently in Phase 3 clinical development for the treatment of anemia associated with myelodysplastic syndrome (MDS) in the U.S. and in Phase 2/3 development for MDS in China.
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer and has been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). Pamrevlumab has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with locally advanced unresectable pancreatic cancer. Across all trials, pamrevlumab has consistently demonstrated a good safety and tolerability profile to date. For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the company's product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory, and commercial plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "will", "should," "on track," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Condensed Consolidated Balance Sheets
| June 30, 2018 | December 31, 2017 (1) | ||||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 643,803 | $ | 673,658 | |||
| Short-term investments | 28,094 | 62,060 | |||||
| Accounts receivable | 30,189 | 8,452 | |||||
| Prepaid expenses and other current assets | 17,997 | 4,800 | |||||
| Total current assets | 720,083 | 748,970 | |||||
| Restricted time deposits | 5,181 | 5,181 | |||||
| Long-term investments | 10,587 | 10,506 | |||||
| Property and equipment, net | 128,829 | 129,476 | |||||
| Other assets | 5,239 | 4,517 | |||||
| Total assets | $ | 869,919 | $ | 898,650 | |||
| Liabilities, stockholders' equity and non-controlling interests | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,222 | $ | 5,509 | |||
| Accrued liabilities | 49,492 | 63,781 | |||||
| Deferred revenue | 37,845 | 16,670 | |||||
| Total current liabilities | 90,559 | 85,960 | |||||
| Long-term portion of lease financing obligations | 97,473 | 97,763 | |||||
| Product development obligations | 16,981 | 17,244 | |||||
| Deferred rent | 3,350 | 3,657 | |||||
| Deferred revenue, net of current | 137,436 | 138,241 | |||||
| Other long-term liabilities | 9,318 | 8,047 | |||||
| Total liabilities | 355,117 | 350,912 | |||||
| Total stockholders' equity | 495,531 | 528,467 | |||||
| Non-controlling interests | 19,271 | 19,271 | |||||
| Total equity | 514,802 | 547,738 | |||||
| Total liabilities, stockholders' equity and non-controlling interests | $ | 869,919 | $ | 898,650 |
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2018 | 2017 (1) | 2018 | 2017 (1) | ||||||||||||
| (Unaudited) | (Unaudited) | (1) | |||||||||||||
| Revenue: | |||||||||||||||
| License revenue | $ | 14,323 | $ | - | $ | 14,323 | $ | - | |||||||
| Development and other revenue | 29,629 | 30,268 | 61,553 | 59,710 | |||||||||||
| Total revenue | 43,952 | 30,268 | 75,876 | 59,710 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 52,138 | 46,981 | 109,112 | 93,713 | |||||||||||
| General and administrative | 15,055 | 13,425 | 30,605 | 24,955 | |||||||||||
| Total operating expenses | 67,193 | 60,406 | 139,717 | 118,668 | |||||||||||
| Loss from operations | (23,241 | ) | (30,138 | ) | (63,841 | ) | (58,958 | ) | |||||||
| Interest and other, net: | |||||||||||||||
| Interest expense | (2,750 | ) | (2,757 | ) | (5,519 | ) | (5,132 | ) | |||||||
| Interest income and other, net | 2,646 | 1,031 | 4,717 | 1,677 | |||||||||||
| Total interest and other, net | (104 | ) | (1,726 | ) | (802 | ) | (3,455 | ) | |||||||
| Loss before income taxes | (23,345 | ) | (31,864 | ) | (64,643 | ) | (62,413 | ) | |||||||
| Provision for income taxes | 75 | 48 | 174 | 109 | |||||||||||
| Net loss | $ | (23,420 | ) | (31,912 | ) | $ | (64,817 | ) | $ | (62,522 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.28 | ) | $ | (0.46 | ) | $ | (0.78 | ) | $ | (0.94 | ) | |||
| Weighted average number of common shares used to calculate net loss per share - basic and diluted | 83,750 | 69,638 | 83,309 | 66,853 |
Vice President, Investor Relations and Corporate Communications